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Uveitis	is	a	heterogeneous	group	of	infectious	and	non-infectious	intraocular	1	 inflammatory	diseases.	Management	of	both	subsets	of	uveitis	is	frequently	challenging.1	2	 Since	2000,	advances	in	microbial	diagnostics	and	introduction	of	biologic	drugs,	3	 combined	with	the	potential	for	electronic	communication	to	facilitate	research	on	4	 diseases	with	low	incidence,	have	provided	uveitis	specialists	with	unprecedented	5	 opportunities	for	clinical	trials	to	establish	evidence-based	management	algorithms.	6	 Hampering	this	effort,	however,	was	lack	of	a	common	system	for	describing	uveitis,	7	 including	diagnosis,	severity	and	outcome.2		8	 	9	 The	Standardization	of	Uveitis	Nomenclature	(SUN)	Project	is	an	effort	to	develop	10	 “international	consensus	for	the	use	of	terms	to	report	on	uveitis	at	academic	meetings	11	 and	in	the	literature.”3	The	first	phase	of	the	project	brought	together	an	international	12	 group	of	45	uveitis	specialists	–	the	SUN	Working	Group	–	and	used	nominal	group	13	 techniques	to	reach	consensus	on	nomenclature	for	presenting	clinical	data,	including	14	 uveitis	terminology,	grading	of	inflammation,	and	reporting	of	outcomes	and	results.	15	 The	product	of	this	collaboration	–	SUN	for	Reporting	Clinical	Data	–	was	published	in	16	 2005.4	The	report	has	over	1500	citations,	and	in	an	editorial	published	in	2013,	SUN	17	 Working	Group	leaders	observed,	“investigators	appear	to	be	adopting	these	18	 guidelines”.3	However,	use	of	SUN	for	Reporting	Clinical	Data	in	human	uveitis	studies	19	 has	not	been	formally	evaluated.		20	 	21	 We	reviewed	the	peer-reviewed	literature	in	clinical	uveitis	over	the	12-month	period	22	 that	concluded	10	years	since	publication	of	SUN	for	Reporting	Clinical	Data.	We	chose	23	 this	interval	to	allow	sufficient	time	for	application	of	the	recommendations	in	major	24	 investigator-initiated	clinical	trials.	To	identify	articles	reporting	human	uveitis	studies	25	
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published	between	October	1,	2014	and	September	30,	2015,	the	National	Library	of	26	 Medicine	of	National	Institutes	of	Health	PubMed	database	27	 (www.ncbi.nlm.nih.gov/pubmed)	was	searched	on	three	dates	(September	2,	2015;	28	 October	31,	2015;	February	28,	2016)	using	the	terms,	“uveitis	2014[ppdat]”	and	29	 “uveitis	2015[ppdat]”,	with	“English”	selected	under	the	“Languages”	filter.	Exclusions	30	 included:	articles	reporting	studies	in	non-human	subject	experimental	systems;	meta-31	 analyses;	reviews;	case	reports;	editorials;	correspondence	without	new	clinical	data;	32	 articles	describing	uveitis	incidentally	and	not	reporting	uveitis	patient-related	data;	33	 and	articles	describing	multiple	ophthalmic	conditions,	in	which	uveitis	cases	were	a	34	 minority.		35	 	36	 Articles	were	reviewed	in	a	standardized	manner	with	pre-defined	data	collection	37	 sheets	to	determine	compliance	with	nine	SUN-defined	items	for	reporting	clinical	data:	38	 terminology	(anatomic	classification	and	descriptors	of	uveitis);	grading	inflammation	39	 (grading	of	anterior	chamber	cells,	anterior	chamber	flare	and	vitreous	haze);	and	40	 outcomes	and	results	reporting	(activity	of	uveitis	terminology,	and	reporting	of	41	 corticosteroid-sparing,	follow-up	and	visual	acuity	outcome).4	Use	of	a	SUN-defined	item	42	 was	judged	as:	compliant	if	an	article	reported	use	of	the	item	as	described	in	the	43	 recommendations;	non-compliant	if	an	article	reported	use	of	the	item	incorrectly	or	44	 used	a	non-SUN	reporting	system;	and	partially	compliant	if	an	article	described	a	study	45	 that	used	some	aspects	of	the	item	correctly	and	other	aspects	incorrectly,	or	if	SUN	and	46	 non-SUN	reporting	systems	were	combined	to	describe	the	item.		47	 	48	 Fourteen	publication	characteristics	were	collected:	journal	impact	factor;	numbers	of	49	 authors,	author	institutions	and	author	countries;	senior	author	clinical	specialty,	50	
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institution	type	and	country;	type	of	study;	type	of	uveitis;	sample	size;	and	for	clinical	51	 studies,	course,	level	of	evidence	and	primary	outcome.	Citation	of	SUN	for	Reporting	52	 Clinical	Data4	was	also	recorded.	Highly	skewed	explanatory	variables	that	were	initially	53	 collected	as	continuous	variables	were	divided	into	appropriate	categories.	For	SUN-54	 defined	items	applicable	to	at	least	100	articles,	Chi	square	or	Fisher’s	exact	tests	were	55	 used	to	assess	associations	between	compliance	with	SUN	for	Reporting	Clinical	Data	56	 and	13	categorical	publication	characteristics,	and	two-sample	t-test	was	used	to	assess	57	 associations	between	compliance	and	journal	impact	factor;	in	these	analyses,	partially	58	 compliant	was	considered	non-compliant.	59	 	60	 From	a	total	of	1665,	206	articles	qualified	for	review,	including	translational	(17%),	61	 and	prospective	(19%)	and	retrospective	(64%)	clinical	studies,	published	in	diverse	62	 journals,	by	groups	of	authors	practicing	within	and	outside	ophthalmology,	and	in	US	63	 and	non-US	institutions.	Publication	characteristics	are	presented	in	Table	S1	(available	64	 at	www.aaojournal.org).	Compliance	with	SUN-recommended	reporting	in	applicable	65	 studies	varied	according	to	item	(Table	1):	anatomic	classification	of	uveitis	(53%	of	66	 205);	descriptors	of	uveitis	(29%	of	185);	grading	schemes	for	anterior	chamber	cell	67	 (65%	of	62),	anterior	chamber	flare	(42%	of	19)	and	vitreous	haze	(50%	of	40);	activity	68	 of	uveitis	terminology	(32%	of	50);	and	reporting	of	corticosteroid	sparing	(63%	of	19),	69	 follow-up	(50%	of	105)	and	visual	acuity	outcome	(18%	of	107).		70	 	71	 Associations	between	publication	characteristics	and	compliant	use	of	SUN-defined	72	 items	were	tested	for:	anatomic	classification;	descriptors	of	uveitis;	reporting	of	follow-73	 up;	and	reporting	of	visual	acuity	outcome.	Results	of	these	analyses	are	presented	in	74	 Table	S2	(available	at	www.aaojournal.org).	Publication	characteristics	significantly	75	
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associated	with	correct	use	of	one	or	more	items	of	the	nomenclature	included:	higher	76	 journal	impact	factor;	uveitis-specialized	ophthalmologist	as	senior	author;	multiple	77	 countries	involved	in	the	research;	heterogeneous	or	mixed	diagnostic	type	of	uveitis;	78	 larger	sample	size;	prospective	course	of	study;	epidemiological	or	experimental	design	79	 of	study;	and	medical	or	surgical	interventional	outcome.		80	
	81	 The	SUN	Working	Group	has	advocated	for	the	application	of	SUN	for	Reporting	Clinical	82	 Data	in	all	uveitis	studies	initiated	after	their	report.4	With	the	caveat	that	inclusion	of	83	 English	language	papers	may	skew	towards	use,	we	find	that	10	years	following	84	 publication,	the	recommendations	are	being	widely	incorporated	into	human	uveitis	85	 research.	All	recommendations	are	being	followed,	although	there	is	variation	in	the	86	 implementation	of	different	items,	and	no	item	is	correctly	applied	in	more	than	two-87	 thirds	of	studies.	These	observations	may	indicate	lack	of	awareness,	or	the	validation	of	88	 alternative	methods,	such	as	optical	coherence	tomography	for	inflammation	grading.5	89	 However,	for	some	items,	in	over	50%	of	articles	that	cite	SUN	for	Reporting	Clinical	90	 Data,	authors	do	not	apply	the	nomenclature	correctly,	suggesting	lack	of	understanding	91	 and	need	for	education.	Universal	use	of	one	clinical	nomenclature	for	uveitis	remains	92	 an	important	goal	for	all	practitioners	who	manage	this	complex	group	of	diseases,	and	93	 opportunities	should	be	identified	to	instruct	investigators	on	use	of	SUN	for	Reporting	94	 Clinical	Data.		95	
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